In the atlas acs 2 timi 51 trial, 2,402 patients 15. The antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. Atlas acs 2 timi 51 assigned 15,526 patients with a recent acs to either twice daily 2. The pivotal atlas acs 2 timi 51 study proves xarelto 2. The dualpathway strategy after acute coronary syndrome. Objectivesthe aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes acs in the atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial. An efficacy and safety study for rivaroxaban in patients with. The characteristics and key safety outcomes of included studies are summarized in table 1. Anticoagulation and antiplatelet therapy in acute coronary. Rivaroxaban is a selective direct factor xa inhibitor that is used to prevent and treat venous thromboembolism and to prevent stroke or systemic embolism in atrial fibrillation. Acute coronary syndrome acs is a serious and life threatening condition. Methods study population the study included patients. Rivaroxaban is the only novel oral anticoagulant oac that has finalised a phase iii clinical trial in acute coronary syndrome acs with a. The pivotal atlas acs 2timi 51 study proves xarelto 2.
If the data from atlas acs 2 timi 51 were extrapolated into clinical practice, we could. Antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 51. Culpritonly revascularization to treat multivessel disease after primary pci for stemi. Rivaroxaban in patients stabilized after a stsegment elevation myocardial infarction. Methods trial oversight pioneer afpci was an international, multicenter, randomized, openlabel trial. Timi 51 to evaluate the strategy of combining rivaroxaban with aspirin compared with treatment with aspirin alone in the. Rivaroxaban stemi study hits print as fda delivers setback. Results of the highly anticipated atlas acs 2 timi 51 trial demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. Af and atlas acs 2 timi 51 trials formed the basis of the pioneer afpci trial, which addressed the unmet need of the optimal antithrombotic regimen in patients with both nvaf and coronary artery disease cad. The atlas acs 2timi 51 antixa therapy to lower cardiovascular events in addition to aspirin withwithout thienopyridine therapy in subjects with acute coronary syndrome was a global, double blind, phase iii clinical study involving 15,526 acute coronary syndrome acs.
The atlas acs 2timi 51 study multivu, a cision company. Since factor xa plays a central role in thrombosis, the. The association between baseline wbc count and a composite of thrombolysis in myocardial infarction timi major. The effect of rivaroxaban on myocardial infarction in the. Atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 is the largest study to date to test a novel xa inhibitor, rivaroxaban, in patients with an acute coronary syndrome acs. The effect of rivaroxaban on myocardial infarction in the atlas acs 2 timi 51 trial article in european heart journal. On the basis of the graded increase in bleeding across doses of rivaroxaban in both strata 1 and 2 in conjunction with the efficacy noted at lower doses of the factor xa inhibitor, 25 mg and 5 mg of rivaroxaban administered twice daily have been selected for further assessment in a large, phase iii clinical trial atlas acs 2timi 51. Rivaroxaban meets primary endpoint in atlas acs timi 51. Nov, 2011 results of the highly anticipated atlasacs 2timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. The atlas acs 2 timi 51 trial and the burden of missing data antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome acs 2 thrombolysis in myocardial infarction 51 mori j.
An efficacy and safety study for rivaroxaban in patients with acute. Atlas acs2, timi 51 2012 randomized 15,342 patients with recent acs to either twicedaily doses of either 2. Rivaroxaban is not fda approved in the acs setting or in patients with atrial fibrillation undergoing stent placement. Subjects are to receive lowdose aspirin therapy 75 to 100 mgday, and enrollment will be stratified based. All patients were to receive standard medical therapy, including lowdose aspirin. Reduction of stent thrombosis in patients with acute coronary. Atlas acs 2timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. Michael gibson, ms, md on behalf of the atlas acs 2. Dec 17, 2008 gibson cm, chakrabarti ak, mega j, bode c, bassand jp, verheugt fw, bhatt dl, goto s, cohen m, mohanavelu s, burton p, stone g, braunwald e.
The primary efficacy mace end point of cv death, mi and stroke was significantly reduced risk with both doses of rivaroxaban. Atlas acs 2 timi 51 was arandomized, double blinded, placebo controlled trial that enrolled 15,526 subjects with an acs to either placebo or rivaroxaban. Atlas timi 51 jungwon suh seoul national university, korea potent platelet inhibition is a cornerstone in the management of acute coronary syndrome acs. Jul 23, 20 reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in atlas acs 2 timi 51. Reduction of stent thrombosis in patients with acute. The primary efficacy endpoint in the phase iii atlas acs 2 timi 51 study was the. Michael gibson, ms, md on behalf of the atlas acs 2 timi. Antithrombotic therapy in patients with recent acs. Atlas acs 2timi 51 rivaroxaban xarelto stemi study. Krantz, md,yz sanjay kaul, mdxk aurora and denver, colorado. For full access to this pdf, sign in to an existing account, or.
Scuoladispecializzazioneinmalaedellapparatocardiovascolare dire8oreprof. Atlas acs2timi51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction51 is the largest study to date to test a novel xa inhibitor, rivaroxaban, in patients with an acute coronary syndrome acs. Standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2timi 51 are listed in the supplementary appendix, available at. A major subanalysis of the atlas acs 2timi 51 study in 7,817 acs patients with a recent stemi demonstrated that xarelto 2. Gibson cm1, chakrabarti ak, mega j, bode c, bassand jp, verheugt fw, bhatt dl, goto s, cohen m, mohanavelu s, burton p, stone g, braunwald e. Events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. Nice issues interim appraisal consultation document acd. The atlas acs 2 timi 51 trial found rivaroxaban reduced the risk for the composite endpoint of death from cardiovascular causes, mi or stroke vs. An efficacy and safety study for rivaroxaban in patients. Rivaroxaban in patients with a recent acute coronary syndrome article pdf available in new england journal of medicine 3661. Read the atlas acs 2 timi 51 trial and the burden of missing data, journal of the american college of cardiology on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Atlas acs 2timi 51 is a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. Efficacy and safety data are consistent with results of the. Applying the spectrum of antithrombotic therapies to your. Rivaroxaban for preventing adverse outcomes after acute. Patients were enrolled into the trial within 7 days of being admitted to hospital for acute coronary syndrome. This study pools data from atlas acs timi 46 acute coronary syndromethrombolysis in myocardial infarction 46 trial and atlas acs 2 timi 51 to evaluate the strategy of combining rivaroxaban with aspirin compared with treatment with aspirin alone in the. Rivaroxaban and antiplatelet agents in the atlas acs 2 timi 51 trial. The mah must agree the content and format of the prescriber guide together with a. Bayer has announced that the oral anticoagulant, rivaroxaban, has reduced ischaemic events but increased bleeding in acute coronary syndrome acs patients in the largescale trial atlas acs 2 timi 51. Timi 51 investigated the efficacy and safety of rivaroxaban among men and women, more than 18. Fulltext article available only as a pdf file for download. Syndrome acs 2thrombolysis in myocardial infarction 51.
After stabilisation of the acute coronary syndrome and after. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. The company said the drug was associated with a statistically significant reduction in the primary composite end. The trial was sponsored by janssen scientific affairs and bayer.
Safety and efficacy of rivaroxaban when added to aspirin. The safety of direct oral anticoagulants with p2y12. Prevention of bleeding in patients with atrial fibrillation. Rivaroxaban in patients with a recent acute coronary syndrome. Ticagrelor nda 22433 briefing document for cardiovascular and renal.
Approvability of rivaroxaban was considered largely on the basis of the atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome acs 2 thrombolysis in myocardial infarction 51 trial, which demonstrated a significant reduction in a composite of cardiovascular death, myocardial infarction, and stroke. Cantos results show antiinflammatory therapy lowers. The effect of rivaroxaban on myocardial infarction in the atlas acs 2 timi 51 trial. On the basis of the graded increase in bleeding across doses of rivaroxaban in both strata 1 and 2 in conjunction with the efficacy noted at lower doses of the factor xa inhibitor, 2 5 mg and 5 mg of rivaroxaban administered twice daily have been selected for further assessment in a large, phase iii clinical trial atlas acs 2 timi 51. After an acute coronary syndrome, patients remain at risk for. The atlas acs 2timi 51 trial and the burden of missing data. Rivaroxaban reduces events in atlasacs the british. In a recent viewpoint in jacc two members of the fdas cardiovascular and renal drugs advisory committee, mori krantz and sanjay kaul, write about the problem of missing data in the atlas acs 2 timi 51 trial and consider some of the larger implications of missing data in clinical trials. Lowdose rivaroxaban reduced mortality in patients with a.
Atlas acs 2timi 51 rivaroxaban xarelto stemi study published. Pdf acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Acute cardiovascular care 45 october 2014 with 55 reads. Results of the highly anticipated atlas acs 2 timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the. In the atlas acs 2timi 51 trial, 2,402 patients 15. Ticagrelor has demonstrated survival benefits for patients with acs and has been recommended as a drug of choice in the current practice guidelines. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in atlas acs 2 timi 51. The primary outcome is positive is that good enough. Noacs beyond atrial fibrillation february 24 2017 16. Atlas acs 2timi 51 a total of 983 primary outcome events would provide a power of 96% to detect a 22. Atlas acs 2timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atoll acute myocardial infarction treated with primary angioplasty and intravenous enoxaparin or unfractionated heparin to lower ischaemic and bleeding events at. Rivaroxaban for pre xaban for preventing adv enting adverse. A subset of patients had their wbc count measured at baseline. Characteristics, treatments and outcomes of patients with acute coronary.
The atlas acs 2timi 51 trial and the burden of missing data antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome acs 2thrombolysis in myocardial infarction 51 mori j. Antixa therapy to lower cardiovascular events in addition to aspirin with or without thienopyridine therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 46 trial 2009 condition. Use of direct oral anticoagulants in triple therapy. The main study is the atlas acs2timi 51 study the second trial of. Atlas acs 2 timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. Pr evention of bleeding in patients wi th atrial fibrillation undergoing pci. The atlas acs 2timi 51 trial and the burden of missing. The association between baseline wbc count and a composite of thrombolysis in myocardial infarction timi major bleeding or timi minor. Us fda briefing document albeit in the whole trial population of. Whether that risk can be safely reduced by adding an anticoagulant to post acs therapy was addressed in the atlas acs 2 timi 51 trial, which found that rivaroxaban was associated with a reduction in. Polish registry of acute coronary syndromes pl acs. Bayer ag announced today that the atlas acs timi 51 trial of rivaroxaban xarelto, bayer and johnson and johnson in patients with acute coronary syndrome acs.
Rivaroxaban in patients stabilized after a stsegment. One of the authors, sanjay kaul, agreed to answers questions about the topic from cardioexchanges. Appraise 2 the second apixaban for prevention of acute ischemic events trial50 atlas acs 2 timi 51 the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial49 atollthe acute stemi treated with primary pci and intravenous. Briefing document for cardiovascular and renal drugs advisory.
310 276 839 486 982 38 41 289 1417 618 1005 1520 1637 1208 1338 100 1290 1617 812 728 770 421 136 1331 336 604 244 872 96 195 342 1357